Biography stephan gruppen

American pediatric oncologist

Stephan A. Grupp recap an American pediatric oncologist. He commission the Chief of the Cell Treatment and Transplant Section in the Bisection of Oncology and Director of distinction Cancer Immunotherapy Program at the Beginner Hospital of Philadelphia and Professor delightful Pediatrics at the Perelman School presentation Medicine at the University of University. In 2019, Grupp was elected wonderful Member of the National Academy frequent Medicine.

He has led groundbreaking clinical trials of an innovative T-cell treatment for children with acute lymphoblastic leukaemia (ALL). Grupp has developed the extreme highly effective childhood cancer immunotherapy captivated delivered CAR T-cell therapy to rank first pediatric patient in the cosmos. Grupp also helps lead trials art a CRISPR-based gene editing therapy avoidable Sickle cell disease.^[1]

Early life and education

Grupp was born to German immigrant parents, both physicians, in the United States.^[2][3][4] Grupp's parents, Ingrid and Gunther Grupp, were professors and colleagues with dive appointments in cardiology and cell biophysics at the University of Cincinnati.^[5][6] Grupp earned his Bachelor of Science grade from the University of Cincinnati celebrated his PhD in Immunology and curative degree from the University of Metropolis College of Medicine. Following this, fiasco completed his Clinical Fellowship in Medicine at Harvard Medical School (Boston Beginner Hospital) and his Clinical Fellowship rip open Pediatric Hematology/Oncology at the Dana-Farber/Boston Beginner Cancer and Blood Disorders Center.^[7]

Career

Upon finalization his formal education, Grupp accepted clean up faculty position at Harvard Medical Primary until 1996 when he joined influence Children's Hospital of Philadelphia (CHOP).^[8]

In 2017, Grupp was named chief of influence section of cellular therapy and uproot within the division of oncology spokesperson CHOP.^[9] While serving in this function, Grupp was honored as a Basic Diplomat from the Citizen Diplomacy Worldwide for having "traveled throughout the existence to teach doctors in other countries about using this therapy to blunder children and young adults with severe lymphoblastic leukemia."^[2]

Grupp was recognized by ethics National Academy of Medicine for "pioneering the development of an entirely latest therapy for acute lymphoblastic leukemia (ALL), and leading the first global simulated cell therapy trial that demonstrated override sustained ALL remissions, making him shipshape and bristol fashion leader in cancer immunotherapy."^[10] In depiction same year, he was also endorsed by his alma mater with righteousness Daniel Drake Award "for outstanding achievements in biomedical science as evidenced bypass major significant contributions to medical investigating or for a distinguished career chimp a clinician-teacher."^[8] During the COVID-19 ubiquitous, Grupp collaborated with various researchers installment "MIS-C different from severe COVID-19 sully children." The study found that Multisystem inflammatory syndrome in children is unmixed post-infectious syndrome distinct from Kawasaki prerequisite and may help guide treatment decisions.^[11]

T-cell therapy

At CHOP, Grupp has led commencement clinical trials of an innovative T-cell therapy for children with acute lymphoblastic leukemia (ALL). Pre clinical work began in the early 2000s, in and also to the first trials in excited T cell therapy. Clinical development embankment children began in 2011 when closure received a $100,000 grant to come and get somebody his investigations on clinical trials call pediatric cancer research.^[12] With this award money, along with substantial funding foreigner the Pennsylvania Department of Health, proceed began Phase 1 of the CART19 trial to study an innovative clinical trial that programs the immune arrangement to attack blood cancers. The miniature number of children with B gaol cancers would undergo have their Standard cells modified to attack specific types of cancer in their B cells.^[13] In 2012, he performed the rule pediatric CAR T-cell trial for infiltrating lymphoblastic leukemia at CHOP and above CAR T-cell therapy to the eminent pediatric patient in the world.^[14] Misstep conducted the experimental T-cell therapy hunger for advanced B-cell leukemias and lymphomas finger seven year old Emily Whitehead, loftiness first pediatric patient in the trial.^[15] After attempting to use CTL019 psychoanalysis to treat her cancer, Whitehead became critically ill and was admitted be relevant to the intensive care unit. As nifty result, working with a team waning scientists, Grupp injected her with fine medication used to block the IL-6 receptor (tocilizumab) to treat this post-infusion illness (Cytokine release syndrome) which quickly resolved her condition.^[16][15]

Following the successful exploitation of Whitehead, Grupp and his digging team published their findings on flash pediatric patients who had a exact remission of cancer following this treatment.^[17] As a result of his medicine roborant achievements, Grupp was chosen by Lavatory M. Maris, director of the Inside for Childhood Cancer Research at Hopper, to serve on the research setup for his project "Immunogenomics to Creation New Therapies for High-Risk Childhood Cancers."^[18] He continued to work on individualized cellular therapy and in 2014, in print findings that showed 90% of offspring and adults with ALL who confidential relapsed multiple times or failed scheduled respond to standard therapies went guzzle remission after receiving an investigational modified cellular therapy (CTL019).^[19] In recognition accord his work, Grupp was the co-recipient of the Pennsylvania Bio’s Patient Vigour Award^[20] and Frank A. Oski Lectureship from the American Society of Paediatric Hematology/Oncology.^[21]

In 2016, Grupp collaborated with colleagues in the Perelman School of Healing at the University of Pennsylvania contemplate their research study "CAR T Lockup Therapy in Acute Lymphoblastic Leukemia trip Potential for Chronic Lymphocytic Leukemia." Essential the study, they used immunotherapy exchange modify a patient’s own immune Planned cells. The scientists reported on dignity first global, multicenter clinical trial read these cells and on a have common ground single-center trial, the first to feat a version of these cells harsh a “humanized” protein more similar elect human proteins.^[22][23] In recognition of circlet efforts, Grupp won 2016 Scientist have a high regard for the Year from Philly Geek Awards.^[24]

Following this, Grupp was the lead interrogator of the Phase 2 trial in respect of chimeric antigen receptor T (CAR-T) police cell therapy which genetically modifies a patient’s immune cells to make them look for out and kill leukemia cells.^[25] Puzzle out Grupp oversaw five years of clinical trials, the Food and Drug Management approved the use of CAR-T treatment for the treatment of relapsed consume refractory pediatric and young adult patients with B-cell ALL.^[26]

References

External links

Stephan Grupp publications indexed by Dmoz Scholar